Xiaowen Wu

发表

Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma.

C. Cui, L. Si, Z. Chi, 2018, Human Pathology.

Clinical significance of CCNE1 copy number gain in acral melanoma patients

Y. Kong, Jun Guo, Xiaowen Wu, 2021, Melanoma research.

Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.

Li Zhou, X. Bai, C. Cui, 2022, Clinical genitourinary cancer.

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

C. Cui, B. Lian, L. Si, 2017, Clinical Cancer Research.

Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma

Fenghao Zhang, Y. Kong, Xiaowen Wu, 2022, Genes.

FMRP ligand circZNF609 destabilizes RAC1 mRNA to reduce metastasis in acral melanoma and cutaneous melanoma

T. Jiao, Q. Shang, Fenghao Zhang, 2022, Journal of experimental & clinical cancer research : CR.

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Qing Yang, Li Zhou, X. Bai, 2022, BMC Cancer.

Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma

C. Cui, L. Si, Z. Chi, 2018, Journal of Cancer.

Pathological impact and medical applications of electromagnetic field on melanoma: A focused review

Y. Kong, Xiaowen Wu, Qian Guo, 2022, Frontiers in Oncology.

Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing

Jinyu Yu, Ting Yin, C. Cui, 2019, Journal of Cancer.

Methylation of O6-methylguanine DNA methyltransferase promoter is a predictive biomarker in Chinese melanoma patients treated with alkylating agents

L. Si, Z. Chi, X. Sheng, 2018, Translational Cancer Research.

Frequency of CDK2 , CCNE1 Copy Number Variation in Acral Melanoma and Implications for CDK Inhibitor in Targeted Therapy

Jinyu Yu, Ting Yin, Y. Kong, 2020 .

MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients

Jinyu Yu, Y. Kong, Jun Guo, 2020, Clinical and Experimental Medicine.

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

K. Flaherty, Jinyu Yu, Li Zhou, 2019, Clinical Cancer Research.

Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis

S. Cang, Xiaowen Wu, Jiayi Yu, 2020, Frontiers in Oncology.

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

C. Cui, L. Si, Z. Chi, 2018, Journal of Hematology & Oncology.

Prognostic role of NRAS isoforms in Chinese melanoma patients

Y. Kong, Jun Guo, Tianxiao Xu, 2019, Melanoma research.

Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.

K. Brown, X. Bai, C. Cui, 2018, European journal of cancer.

S. Cang, Y. Kong, Xiaowen Wu, 2022, Frontiers in Immunology.

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Xiaowei Xu, C. Cui, L. Si, 2015, Clinical Cancer Research.

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon

C. Cui, L. Si, Z. Chi, 2017, Translational oncology.

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

C. Cui, L. Si, Z. Chi, 2018, Cancer biology & therapy.

Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.

Li Zhou, X. Bai, C. Cui, 2022, Clinical genitourinary cancer.

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy

Siming Li, C. Cui, B. Lian, 2017, Journal of Translational Medicine.

Analysis of TSC1 mutation spectrum in mucosal melanoma

C. Cui, L. Si, Z. Chi, 2018, Journal of Cancer Research and Clinical Oncology.

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways

Li Zhou, X. Bai, C. Cui, 2019, Theranostics.

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma

C. Cui, L. Si, Z. Chi, 2017, Oncology letters.

The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma.

Jinyu Yu, Ting Yin, Y. Kong, 2020, Clinical science.

High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis

C. Cui, L. Si, Z. Chi, 2018, Cancer science.

Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma.

C. Cui, L. Si, Z. Chi, 2017, Oncology letters.

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis

K. Flaherty, Xiongwen Tang, Li Zhou, 2022, Journal for ImmunoTherapy of Cancer.

Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

C. Cui, Y. Kong, Jun Guo, 2019, Journal of Translational Medicine.

Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics

C. Cui, L. Si, Z. Chi, 2018, Melanoma research.

Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response

S. Cang, Xiaowen Wu, Junya Yan, 2023, Journal of Cancer Research and Clinical Oncology.

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population

Li Zhou, X. Bai, C. Cui, 2023, The oncologist.

Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma.

Hongqian Guo, Li Zhou, X. Bai, 2022, Journal of Clinical Oncology.

Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma.

D. Cao, Li Zhou, Yi-qiang Liu, 2022, Urologic oncology.

Pathological impact and medical applications of electromagnetic field on melanoma: A focused review

Y. Kong, Xiaowen Wu, Qian Guo, 2022, Frontiers in Oncology.

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.

Yue Yang, Li Zhou, X. Bai, 2023, JAMA oncology.

Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial.

Yue Yang, Li Zhou, X. Bai, 2023, European journal of cancer.

Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma

Li Zhou, X. Sheng, Xieqiao Yan, 2023, Bladder.